1.	A Phase III Study of Oral LDE225 Versus (vs) Temozolomide (TMZ) in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: Any age Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225C2301, NCT01708174
2.	A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225X2104, 2010-019348-37, NCT01125800
3.	Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225B2209, 2010-023819-34, NCT01350115
4.	LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: 12-X238, NCT01757327
5.	Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225X2203, NCT01826214
6.	An East Asian Study of LDE225 Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225X1101, NCT01208831
7.	Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107Y2101, 2011-000282-12, NCT01456676
8.	LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 72 Sponsor: Other Protocol IDs: 11-164, NCT01485744
9.	Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225X2103, 2010-024218-70, NCT01487785
10.	Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225X2114, 2011-005016-28, NCT01576666
11.	Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-206, NCT01579929
12.	Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225A2112, NCT01769768
13.	Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SKIN0009, SU-09022011-8371, 21759, NCT01529450
14.	A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 071108, 0220120066, NCT01694589